StreetInsider.com News Articles

Kane Biotech to Host Commercial Update Webcast on September 16

Wed, 09 Sep 2026 07:05:00 -0400

WINNIPEG, Manitoba, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will host a virtual Commercial Update on Wednesday, September 16, 2026, at 11:00 a.m. Eastern Time.

The one-hour webcast will provide shareholders, prospective investors and other stakeholders with an update on Kane’s focus on building a clinically credible and commercially disciplined wound-care business, including the Company’s strategy to convert revyve® into meaningful, recurring revenue through sustained clinical adoption, productive commercial channels and

Kane Biotech to Host Commercial Update Webcast on September 16

Wed, 09 Sep 2026 07:05:00 -0400

Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.

Wed, 02 Sep 2026 07:05:00 -0400

WINNIPEG, Manitoba, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) is pleased to announce that it has entered into a non-exclusive distribution agreement with Ontario Medical Supply Inc. ("OMS"), an Ottawa-based medical supply distributor serving the Canadian market.

U.S. FDA 510(k) cleared and Health

Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.

Wed, 02 Sep 2026 07:05:00 -0400

WINNIPEG, Manitoba, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) is pleased to announce that it has entered into a non-exclusive distribution agreement with Ontario Medical Supply Inc. ("OMS"), an Ottawa-based medical supply distributor serving the Canadian market.

U.S. FDA 510(k) cleared and Health

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium

Tue, 25 Aug 2026 07:25:00 -0400

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.